ARCEDI Products
With ‘EVITA TEST COMPLETE’ ARCEDI is the first company to provide genome-wide analysis of the fetus using circulating fetal cells
ARCEDI offers two products for prenatal genetic testing – the third one is in the development phase. All these products are based on our unique fetal-cell-based technology that only requires a blood sample from the mother. The tests offer the most comprehensive and accurate results on the market for Non-Invasive Prenatal Tests.
EVITA TEST COMPLETE
EVITA TEST COMPLETE analyses the DNA of the fetus rendered by circulating fetal cells and detects chromosomal and sub-chromosomal aberrations. It is the only non-invasive prenatal test on the market that examines all the fetus’ chromosomes.
EVITA TEST GENDER
EVITA TEST GENDER analyses the fetal DNA for the presence or absence of Y-chromosome specific genes. Presence of these genes would indicate the presence of a male fetus. The test can be performed from week 10 of the pregnancy. However, due to Danish legislation the results will be revealed earliest at week 12 of the pregnancy.
EVITA TEST COMPLETE
EVITA TEST COMPLETE analyses the DNA of the fetus rendered by circulating fetal cells and detects chromosomal and sub-chromosomal aberrations. It is the only non-invasive prenatal test on the market that examines all the fetus’ chromosomes.
EVITA TEST GENDER
EVITA TEST GENDER analyses the fetal DNA for the presence or absence of Y-chromosome specific genes. Presence of these genes would indicate the presence of a male fetus. The test can be performed from week 10 of the pregnancy. However, due to Danish legislation the results will be revealed earliest at week 12 of the pregnancy.
Pipeline
EVITA TEST CF
EVITA TEST CF analyses the DNA of the fetus and detects any risk of the fetus having cystic fibrosis.
